Bluejay Diagnostics reports SYMON-II dataset: 777 patients, ~18% 28-day mortality for IL-6 evaluation
Bluejay Diagnostics reported preliminary SYMON-II data with 777 patients, an 18% 28-day mortality rate, and 39.5% meeting Sepsis-3 criteria for septic shock. The data aims to support the Symphony IL-6 Test's planned 510(k) submission, though the assay is not FDA cleared. The company filed this information with the SEC.
How this was made
The 30-second read
Why it matters
The disclosed mortality and shock rates provide early validation of the test's prognostic value, which could accelerate regulatory approval and commercial adoption.
Market read
First public release of clinical data for Bluejay's IL‑6 test; may affect the stock and peers in the sepsis diagnostics market.
What to watch
Potential competition from larger diagnostic firms and reimbursement uncertainties
Background
Bluejay Diagnostics is a micro‑cap company developing an IL‑6 based test for sepsis prognosis. The SYMON‑II dataset is intended to support a forthcoming 510(k) submission.
Ticker impact
Bluejay Diagnostics filed an 8‑K reporting its SYMON‑II dataset of 777 patients with 18% 28‑day mortality, the first public disclosure of this clinical data.
potential upside as investors price in the clinical progress and future regulatory filing potential
First disclosure of meaningful trial data for a diagnostic product; market typically reacts positively to early clinical milestones.
Market effects
Adds data to the sepsis diagnostics space, may influence peer valuations
U.S. biotech sector
Limited to diagnostic and biotech investors
Counterpoint
Data may be insufficient to move the stock significantly without FDA clearance
Key entities
- companyBluejay Diagnostics, Inc.
Developer of the Symphony IL‑6 diagnostic test
